• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Coya Therapeutics, Inc. - Common Stock (NQ: COYA )

    5.920 +0.450 (+8.23%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 27, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 64,241
    Open 5.400
    Bid (Size) 5.840 (1)
    Ask (Size) 6.160 (7)
    Prev. Close 5.470
    Today's Range 5.400 - 6.013
    52wk Range 4.750 - 10.69
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference
    From Coya Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    -14.94%
    -14.94%
    1 Month
    -10.98%
    -10.98%
    3 Month
    -12.43%
    -12.43%
    6 Month
    -2.31%
    -2.31%
    1 Year
    -22.00%
    -22.00%

    More News

    Read More
    Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces Closing of $10.0 Million Private Placement
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces $10.0 Million Private Placement
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference
    From Coya Therapeutics, Inc.
    Via Business Wire
    This Yelp Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
    Via Benzinga
    Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics to Present at Upcoming Healthcare Conferences
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024
    From Coya Therapeutics, Inc.
    Via Business Wire
    COYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
    From Coya Therapeutics, Inc.
    Via Business Wire
    Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index
    From Coya Therapeutics, Inc.
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.